Items where Author is "Drevs, Joachim"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2011 | 2010 | 2009 | 2007 | 2005 | 2004 | 2003
Number of items: 13.


Pircher, Andreas and Hilbe, Wolfgang and Heidegger, Isabel and Drevs, Joachim and Tichelli, André and Medinger, Michael. (2011) Biomarkers in tumor angiogenesis and anti-angiogenic therapy. International journal of molecular sciences, Vol. 12, H. 10. pp. 7077-7099.

Pircher, Andreas and Medinger, Michael and Drevs, Joachim. (2011) Liver cancer: Targeted future options. World Journal of Hepatology, 3 (2). pp. 38-44.


Drevs, Joachim and Medinger, Michael and Mross, Klaus and Fuxius, Stefan and Hennig, Juergen and Buechert, Martin and Thomas, Anne and Unger, Clemens and Chen, Bee-Lian and Lebwohl, David and Laurent, Dirk. (2010) A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Research, 30 (6). pp. 2335-2339.


Medinger, Michael and Esser, Norbert and Zirrgiebel, Ute and Ryan, Anderson and Jürgensmeier, Juliane M. and Drevs, Joachim. (2009) Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer Research, 29 (12). pp. 5065-5076.


Steinbild, Simone and Arends, Jann and Medinger, Michael and Häring, Brigitte and Frost, Annette and Drevs, Joachim and Unger, Clemens and Strecker, Ralph and Hennig, Jürgen and Mross, Klaus. (2007) Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie, 30 (12). pp. 629-635.

Unger, Clemens and Häring, Brigitte and Medinger, Michael and Drevs, Joachim and Steinbild, Simone and Kratz, Felix and Mross, Klaus. (2007) Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clinical Cancer Research, 13 (16). pp. 4858-4866.

Drevs, Joachim and Siegert, Patrizia and Medinger, Michael and Mross, Klaus and Strecker, Ralph and Zirrgiebel, Ute and Harder, Jan and Blum, Hubert and Robertson, Jane and Jürgensmeier, Juliane M. and Puchalski, Thomas A. and Young, Helen and Saunders, Owain and Unger, Clemens. (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology, 25 (21). pp. 3045-3054.


Mross, Klaus and Drevs, Joachim and Müller, Marianne and Medinger, Michael and Marmé, Dieter and Hennig, Jürgen and Morgan, Bruno and Lebwohl, David and Masson, Eric and Ho, Yu-Yun and Günther, Clemens and Laurent, Dirk and Unger, Clemens. (2005) Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. European Journal of Cancer, 41 (9). pp. 1291-1299.

Medinger, Michael and Drevs, Joachim. (2005) Receptor tyrosine kinases and anticancer therapy. Current Pharmaceutical Design, 11 (9). pp. 1139-1149.


Drevs, Joachim and Fakler, Julia and Eisele, Silke and Medinger, Michael and Bing, Gerlinde and Esser, Norbert and Marmé, Dieter and Unger, Clemens. (2004) Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Research, 24 (3). pp. 1759-1763.

Medinger, Michael and Soltau, Jens and Unger, Clemens and Drevs, Joachim. (2004) Rezeptor-tyrosinkinasen: Angriffspunkte für neue tumortherapien. Medizinische Monatsschrift für Pharmazeuten, 27 (2). pp. 50-59.


Soltau, Jens and Medinger, Michael and Unger, Clemens and Drevs, Joachim. (2003) Bisphosphonate in der onkologie. Medizinische Monatsschrift für Pharmazeuten, 26 (12). pp. 411-417.

Drevs, Joachim and Medinger, Michael and Schmidt-Gersbach, Carmen and Weber, Renate and Unger, Clemens. (2003) Receptor tyrosine kinases: the main targets for new anticancer therapy. Current Drug Targets, 4 (2). pp. 113-121.

This list was generated on Fri Nov 15 10:14:33 2019 CET.